Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: 2-Year Results of the PLANET Study

Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial

JAMA Ophthalmol.

Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, Ming Cheung GC, Zhang Z, Leal S, Ishibashi T, for the PLANET Investigators

Retinal DiseasesFurther Publications

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK

Br J Ophthalmol

Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, Lee WK, Chang AA, Monés J, D'Souza D, Weissgerber G, Gedif K, Koh A

doi: 10.1136/bjophthalmol-2021-319090

Macular Diseases

Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial

JAMA Ophthalmol.

Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK; EVEREST II study group

doi: 10.1001/

Uveitis

Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program

Ophthalmology.

Merrill PT, Clark WL, Banker AS, Fardeau C, Franco P, LeHoang P, Ohno S, Rathinam SR, Ali Y, Mudumba S, Shams N, Nguyen QD, Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Study Group.

doi: 10.1016/j.ophtha.2020.03.033.

Macular Diseases

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Eye (Lond).

Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.

doi: 10.1038/s41433-018-0114-3.

Cornea and Corneal DiseasesConjunctivitisBlindness and Vision ImpairmentFlammer SyndromeGlaucoma and Ocular PressureLensesMacular DiseasesOcular OncologyRetinal DiseasesSurgery and InterventionUveitisCataractsDry Eye Disease

Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study

Acta Ophthalmol

Li X, Zhu Q, Egger A, Chang L, Wolf S, Song Y, Zhang J, Dong F, Xu X, Weisberger A

doi: 10.1111/aos.14588

Macular Diseases

EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: THE ARIES STUDY

Retina

Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, Lambrou G, Schmelter T, Wolf S

doi: 10.1097/IAE.0000000000003128

Macular DiseasesRetinal Diseases

Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study

Br J Ophthalmol

Liu K, Wang H, He W, Ye J, Song Y, Wang Y, Liu X, Wu Z, Chen S, Fan K, Liu Y, Zhang F, Li Z, Liu L, Zhang J, Zhang X, Ye J, Liang X, Li X, Ke X, Wu Q, Li J, Tao S, Wang X, Rosenfeld P, Heier JS, Kaiser P, Xu X

doi: 10.1136/bjophthalmol-2020-318690

Macular Diseases

One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysis

Acta Ophthalmol.

Guo MY, Cheng J, Etminan M, Zafari Z, Maberley D

doi: 10.1111/aos.13825.

Related content

Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK

Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial

Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study

EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: THE ARIES STUDY

Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study

One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysis